MammaPrint & 3-year outcome of CT with/without anthracycline-ASCO 2024

Association of MammaPrint index and 3-year outcome of patients in the FLEX Registry trial with HR+HER2- early-stage breast cancer treated with chemotherapy with or without anthracycline

Read More
2025-05-06T14:53:23-04:00May 31st, 2024|Press Releases|

Agendia Announces New I-SPY2 Data Showcasing Ability of New Signature ImPrintTN

Agendia Announces New Data from I-SPY 2 Showcasing Ability of New Signature ImPrintTN to Predict Immunotherapy Response in Patients with Triple Negative Breast Cancer

Read More
2025-05-06T15:22:15-04:00March 20th, 2024|Press Releases|

Agendia Presents Data from FLEX Study at Miami Breast 2024

Agendia Presents Data at Miami Breast 2024 Demonstrating MammaPrintยฎ + BluePrintยฎโ€™s Ability to Further Stratify Tumor Categories in Hormone-Positive Breast Cancer, Highlighting Response to Different Chemotherapy Regimens

Read More
2025-05-06T15:22:48-04:00March 8th, 2024|Press Releases|

Agendiaยฎ Collaborates with National Cancer Institute, SWOG Cancer Research Network for Phase III Trial; Led by University of Michiganโ€™s Dr. Erin Cobain

SWOG S2206 will use MammaPrintยฎ breast cancer recurrence test to examine response to immunotherapy in women with high-risk HR+ breast cancer.

Read More
2025-05-06T15:24:07-04:00October 31st, 2023|Press Releases|
Go to Top